Non-Hodgkin lymphoma Posts on Medivizor
Navigation Menu

Non-Hodgkin lymphoma Posts on Medivizor

Impact of severe side effects on outcomes of older patients with non-Hodgkin lymphoma

Posted by on May 15, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined whether newer therapies for non-Hodgkin lymphoma (NHL) were associated with higher odds of negative side effects in older patients. The study concluded that NHL patients over age 65 experienced more serious side effects than younger patients, and these side effects were associated with worse outcomes. Some background...

Read More

Does G-B treatment improve survival outcomes for patients with refractory follicular lymphoma?

Posted by on May 12, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the outcomes of patients with indolent (painless) refractory (does not respond to treatment) non-Hodgkin’s lymphoma (NHL) after G-B (obinutuzumab, bendamustine) treatment. This study concluded that G-B improved survival outcomes for NHL patients with similar side effects as bendamustine (Treanda)...

Read More

Reviewing radiation therapy options for patients with relapsed or persistent DLBCL

Posted by on May 11, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study reviewed several studies involving patients with relapsed or refractory (does not respond to treatment) diffuse large B-cell lymphoma (DLBCL) who received radiation therapy (RT). The authors concluded that RT can improve outcomes and disease control for patients with localized disease. Some background Diffuse large B-cell...

Read More

Alternating R-CHOP and R-cytarabine for transplant-ineligible MCL patients

Posted by on May 7, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the safety and effectiveness of a chemotherapy regimen alternating R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R-cytarabine (rituximab combined with cytarabine) for mantle cell lymphoma (MCL) patients ineligible for stem cell transplant (SCT). This study concluded that alternating...

Read More

Does prephase treatment help improve post-chemotherapy outcomes for newly diagnosed DLBCL patients?

Posted by on May 2, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the outcomes of newly diagnosed DLBCL (diffuse large B-cell lymphoma) patients who received prephase treatment before chemotherapy. This study concluded that this treatment before chemotherapy improves symptoms and reduces chemotherapy-related side effects in these patients. Some background Diffuse large B-cell...

Read More

How effective and safe is ibrutinib compared to temsirolimus for relapsed or persistent mantle cell lymphoma?

Posted by on May 2, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the effectiveness and safety of ibrutinib (Imbruvica) versus temsirolimus (Torisel) in patients with relapsed or refractory (does not respond to treatment) mantle cell lymphoma (MCL). This study concluded that ibrutinib significantly improved survival outcomes compared to temsirolimus for these patients. Some background...

Read More

Is rituximab/bendamustine safer and more effective than R-CHOP in patients with grade 3A follicular lymphoma?

Posted by on Apr 18, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of the R-B (rituximab, bendamustine) regimen versus the R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) regimen in patients with grade 3A follicular lymphoma (FL3A). This study concluded that R-B is better tolerated and more effective than R-CHOP, making it a...

Read More

What are the outcomes for lymphoma patients who received TECAM chemotherapy before a stem cell transplant?

Posted by on Apr 18, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study analyzed data from patients with Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL) who received TECAM (etoposide, thiotepa, cytarabine, cyclophosphamide, melphalan) chemotherapy before autoSCT (autologous stem cell transplantation). The authors concluded that TECAM is an effective pre-autoSCT regimen for...

Read More

What are the outcomes for B-cell lymphoma patients who receive salvage treatment for cancer that does not respond to R-CHOP chemotherapy?

Posted by on Apr 10, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the outcomes of different salvage treatments in patients with aggressive B-cell non-Hodgkin lymphoma with PET-positive disease (remaining cancer cells) after R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy. This study concluded that B-cell NHL patients with PET-positive...

Read More

How safe and effective is the combination of ibrutinib, lenalidomide, and rituximab for relapsed or refractory mantle cell lymphoma?

Posted by on Mar 17, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the safety and effectiveness of ibrutinib (Imbruvica), lenalidomide (Revlimid), and rituximab (Rituxan) given together to patients with relapsed or refractory (not responding to treatment) mantle cell lymphoma (MCL). The authors conclude that this combination is effective in these patients, but not better than the...

Read More

Survival outcomes for patients with stage I follicular lymphoma

Posted by on Mar 17, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the outcomes for patients with stage I follicular lymphoma who had their tumors completely removed. The authors concluded that a total resection does not significantly improve patient outcomes after they have received other treatments. Some background Follicular lymphoma (FL) is a type of slow growing non-Hodgkin...

Read More